137 related articles for article (PubMed ID: 25789055)
1. Immunization with mutant HPV16 E7 protein inhibits the growth of TC-1 cells in tumor-bearing mice.
Li YL; Ma ZL; Zhao Y; Zhang J
Oncol Lett; 2015 Apr; 9(4):1851-1856. PubMed ID: 25789055
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
3. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
[TBL] [Abstract][Full Text] [Related]
4. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
[TBL] [Abstract][Full Text] [Related]
5. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model.
Zhou X; Qian X; Zhao Q; Lu Y; Xiong M
Biol Pharm Bull; 2004 Mar; 27(3):303-7. PubMed ID: 14993792
[TBL] [Abstract][Full Text] [Related]
6. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
7. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
Li YL; Liu J; Liu JN; Zhang J
Vaccine; 2011 Aug; 29(35):5959-62. PubMed ID: 21722685
[TBL] [Abstract][Full Text] [Related]
8. [The anti-lung cancer activity of a modified HPV 16 type mE6Δ/mE7 fusion protein based vaccine in an experimental animal model].
Zhou X; Zhao Q; Qian X; Xu C; Lu Y
Zhongguo Fei Ai Za Zhi; 2004 Oct; 7(5):379-82. PubMed ID: 21244786
[TBL] [Abstract][Full Text] [Related]
9. [Immunogenicity of mutant and wild HPV16 DNA vaccines].
Zuo YG; Wang JB; Jin HZ; Yue-hua L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771
[TBL] [Abstract][Full Text] [Related]
10. [Expression of HPV16 E7 protein and preparation of its polyclonal antibody].
Wang B; Tu J; Lv Y; Hou B; Liu Q; Lin X; Chen S; Xue X; Zhu S; Zhang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Feb; 30(2):167-70. PubMed ID: 24491058
[TBL] [Abstract][Full Text] [Related]
11. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
[TBL] [Abstract][Full Text] [Related]
12. Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae.
Sadraeian M; Khoshnood Mansoorkhani MJ; Mohkam M; Rasoul-Amini S; Hesaraki M; Ghasemi Y
Cell J; 2013; 15(2):176-81. PubMed ID: 23862120
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.
Cassetti MC; McElhiney SP; Shahabi V; Pullen JK; Le Poole IC; Eiben GL; Smith LR; Kast WM
Vaccine; 2004 Jan; 22(3-4):520-7. PubMed ID: 14670335
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
[TBL] [Abstract][Full Text] [Related]
15. Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development.
Di Bonito P; Petrone L; Casini G; Francolini I; Ammendolia MG; Accardi L; Piozzi A; D'Ilario L; Martinelli A
Int J Nanomedicine; 2015; 10():3447-58. PubMed ID: 26056443
[TBL] [Abstract][Full Text] [Related]
16. Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal model.
Petrone L; Ammendolia MG; Cesolini A; Caimi S; Superti F; Giorgi C; Di Bonito P
J Transl Med; 2011 May; 9():69. PubMed ID: 21592382
[TBL] [Abstract][Full Text] [Related]
17. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect.
Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M
J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328
[TBL] [Abstract][Full Text] [Related]
18. [Construction of recombinant vaccina virus of HPV16 and its antitumor effect].
Huang W; Tian HW; Ren J; Fan JT; Zhao L; Ruan L
Ai Zheng; 2005 Jul; 24(7):817-22. PubMed ID: 16004807
[TBL] [Abstract][Full Text] [Related]
19. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
[TBL] [Abstract][Full Text] [Related]
20. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
